<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452450</url>
  </required_header>
  <id_info>
    <org_study_id>NL1307</org_study_id>
    <nct_id>NCT02452450</nct_id>
  </id_info>
  <brief_title>Ibuprofen and Paracetamol Pharmacokinetic Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine rates of absorption of Ibuprofen and Paracetamol
      formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the maximum concentration (Cmax) of the reference Ibuprofen</measure>
    <time_frame>0-4hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the first extrapolated non-zero concentration (Tlag)</measure>
    <time_frame>0-4hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum concentration (Tmax)</measure>
    <time_frame>0-4hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the lower therapeutic level reaching at least 5 µg/ml (T5.0) for ibuprofen and paracetamol</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the mid therapeutic level reaching at least 8.4 µg/ml (T8.4) for ibuprofen and 10 µg/ml (T10.0) for paracetamol</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the higher therapeutic level reaching at least 10.0 µg/ml (T10.0) for ibuprofen and 20 µg/ml (T20.0) for paracetamol</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial area under the curve (AUCs) at each nominal blood sampling time-point</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve up to the median Tmax for the ibuprofen reference product (AUCTmaxRef)</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma concentration at each planned nominal time-point (Cn)</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax)</measure>
    <time_frame>0-4hr</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Ibuprofen lysine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen liquid capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Acid</intervention_name>
    <arm_group_label>Ibuprofen acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Lysine</intervention_name>
    <arm_group_label>Ibuprofen lysine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Sodium</intervention_name>
    <arm_group_label>Ibuprofen sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Liquid Capsules</intervention_name>
    <arm_group_label>Ibuprofen liquid capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: &gt; 18 to &lt; 50 years.

          2. Sex: Male and female subjects are eligible for entry.

          3. Female subject of child bearing potential with a negative pregnancy test at the
             screening visit and willing to use an effective method of contraception, if applicable

          4. Female subject of non-child bearing potential with negative pregnancy test at the
             screening visit.

          5. Male subject willing to use an effective method of contraception.

          6. Status: Healthy volunteers with a body mass index of &gt;18 and &lt;30 kg/m2.

          7. Absence of relevant abnormalities in the clinical examination, ECG, drug and safety
             analysis.

          8. Subjects who have given written informed consent

        Exclusion Criteria:

          1. Pregnant or lactating female subjects.

          2. A history of significant disease of any body-system.

          3. Any condition that may currently interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          4. A history of allergy or intolerance (including angio-oedema, urticaria, bronchospasm
             and rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal
             anti-inflammatory drugs (NSAIDs), paracetamol, or the excipients of the formulations.

          5. A history of peptic or duodenal ulcers or gastro-intestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          6. A history of frequent dyspepsia, e.g., heartburn or indigestion.

          7. A history of migraine.

          8. A history of psychotic illness, attempted suicide or parasuicide.

          9. Current smokers and ex-smokers who have smoked within 6 months.

         10. A history of drug abuse (including alcohol).

         11. High consumption of stimulating drinks

         12. Those with positive drugs of abuse screen including alcohol on any occasion throughout
             the study.

         13. Ingestion of a prescribed drug at any time in the 14 days before dosing with study
             medication (excluding hormonal contraceptives and hormone replacement therapy), or
             consumption of enzyme inhibitors or inducers during the previous month (such as
             barbiturates, carbamazepine, erythromycin, phenytoin, etc).

         14. Ingestion of an over-the-counter preparation within 7 days before dosing with study
             medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and
             other NSAIDs and paracetamol.

         15. Donation of blood in quantity in the previous 12 weeks before enrolment into the study

         16. Known human immune deficiency virus (HIV) positive status, or a positive viral
             serology screen.

         17. Topical use of ibuprofen within 7 days before dosing with study medication

         18. Those previously randomised into this study.

         19. Employee at study site.

         20. Partner or first degree relative of the investigator.

         21. Those with an ibuprofen level &gt; 10 ng/ml as determined at pre-study screening visit 2
             (Part 2 (Pivotal Phase) of the study only).

         22. Those who are unwilling to consume gelatin of animal origin (Part 2 (Pivotal Phase) of
             the study only).

         23. Those who have participated in a clinical trial in the previous 12 weeks

         24. Those unable in the opinion of the Investigator to comply fully with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

